Articles tagged with Molecular Targets
Researchers at TTUHSC have identified novel targets for treating stroke, focusing on enhancing neurolysin activity. The study discovered small molecules that can selectively enhance the activity of neurolysin, which showed promise in reducing damage to the brain after a stroke.
A phase Ib study found that combining sotorasib, a KRAS G12C inhibitor, with afatinib, a pan-ErbB tyrosine kinase inhibitor, showed antitumor activity in patients with KRAS-mutant non-small cell lung cancer. The combination demonstrated a high disease control rate and improved efficacy compared to prior therapies.
A peptide-drug conjugate called CBX-12 has been shown to enhance the efficacy of immune checkpoint inhibitors in preclinical cancer models by targeting the acidic environment of cancer cells. The treatment exhibited significantly delayed tumor growth, improved survival, and complete tumor regressions compared to immunotherapy alone.
The MAP Virtual Congress 2021 focuses on integrating tumour sample analysis into daily practice, enabling personalized treatment. Key findings include actionable mutations in patient DNA and the role of the tumour microenvironment in metastasis.
A team of scientists has identified molecular biomarkers associated with sepsis, which could be used to predict patient outcomes and guide treatment. The study found that changes in CD52 expression were linked to good outcomes, while S100A9 acted as a driver of fatal sepsis.
Researchers identified five specific mutations prevalent in Delta Plus infections compared to Delta, highlighting the need for expanded antiviral tools. The findings provide clues on how the virus mutates and evade antibodies produced from previous COVID-19 infections or vaccinations.
Researchers have identified a way to restore the effectiveness of drugs in clinical trials for treating AML by using human alpha(1)-acid glycoprotein (AGP) as a 'decoy' to bind and inhibit FLT3-mutated leukemia cells. The approach has potential for improving patient outcomes, particularly for patients with FLT3-mutated AML.
A study published in Nature Communications reveals the mechanisms of SARS-CoV-2 proteolysis and identifies key cellular substrates with therapeutic potential. The research provides a powerful resource for developing targeted strategies to inhibit the virus, which has caused over 227 million infections and 4.6 million deaths worldwide.
Research by University of Arizona Health Sciences identifies chronic arsenic exposure as a risk factor for developing insulin resistance and glucose intolerance. The study found that prolonged activation of NRF2 protein leads to shifts in metabolic pathways, increasing glucose production in the liver.
Researchers at Kyoto University designed a synthetic molecular code, EnPGC-1, that activates mitochondrial biogenesis in T cells, increasing their numbers and longevity. The approach enhances anti-tumor immunity in mice and improves survival.
Researchers identify molecular targets for improved prostate cancer therapy by comparing genomic changes in cancer cells eradicated and resistant to treatment. The study also finds L1 retrotransposition as a dynamic source of cancer heterogeneity.
Researchers found that viral fossils in Australian marsupials are used to make non-coding RNAs that protect against outside infection. The study suggests that these viral fossils may be helping to immunize animals, potentially providing a mechanism similar to vaccination.
Scientists at CIBFar have discovered the molecular mechanism of SARS-CoV-2's main protease, which enables the virus to replicate in host cells. The study provides valuable insights into the process and has immediate applications for developing antiviral drugs.
The study found that NEAT1 lncRNA interacts with JunD to regulate tight junction assembly and promote EMT induction in head and neck cancer cells. Increased NEAT1 expression correlates with poor disease prognosis.
Researchers developed a modular organic molecular system with customizable properties, creating a potent dye that absorbs light in the near-infrared range. The pigments' electronic switchability makes them suitable for studying electron transfer in photosynthesis and as efficient electron-transporting materials.
Researchers at UB aim to reduce unwanted toxicity in cancer treatments by combining antibody-drug conjugates with payload-binding selectivity enhancers. The five-year study may lead to safer and more effective treatments for 1.8 million US cancer patients.
Researchers identified bioactive substances that modulate cholesterol homeostasis, a common feature among many compounds. These findings suggest potential side effects of active substances and provide new insights into targeting cholesterol homeostasis, which may also impact SARS-CoV-2 infections.
Scientists have made a breakthrough in understanding the behavior of highly reactive chemical compounds by identifying their binding preferences. This knowledge allows for targeted syntheses and binding of hazardous chemicals, revolutionizing the field of chemistry.
A new Raman spectroscopy method has been developed to capture target molecules in small gaps using nano-capillary pumping, enabling ultrasensitive detection of various substances. This breakthrough allows for real-time monitoring of cell behavior and chemical kinetics, with potential applications in medicine and chemistry.
Researchers have identified four potent antiviral compounds targeting the PF74 binding site, exhibiting improved metabolic stability compared to PF74. One compound, analog 20, shows similar submicromolar potency and significantly longer half-life in human liver microsomes.
The April edition of SLAS Discovery features research on PROTACs, targeting protein degradation, and kinase family profiling. Authors apply the Four Pillars Framework to expedite PROTAC development and inform pharmacokinetic-pharmacodynamic understanding.
UC Santa Barbara researchers develop a method to increase both affinity and cooperativity in aptamer-based biosensors, allowing for fine-tuned regulation of receptor properties. This approach enables precision biosensing applications, such as detecting low concentrations of target molecules like chemotherapy drugs.
Researchers have identified NRXN1, a cell adhesion molecule, as a potential target for antibody-drug conjugate (ADC) therapy in small cell lung cancer. The study found that targeting NRXN1 with ADCs exhibited anti-tumor activity in SCLC cells.
Researchers identified 134 previously unknown activities for 38 approved excipients, demonstrating direct activity against biologically relevant molecules. Several excipients exhibit evidence predictive of tissue-level toxicity, including thimerosal and cetylpyridinium.
Researchers have developed Pillar[n]MaxQ molecules that bind neuromuscular blocking chemicals with high specificity and strength. These new molecular containers show promise for eliminating toxins and malodorous substances in water, outperforming existing macrocyclic agents.
Researchers create novel molecular cage that confines and twists target molecules, activating specific chemical bonds. The twist angle can be precisely controlled using stuffing molecules, enabling accelerated reaction rates.
Researchers at Kyoto University have improved the efficiency of organic solar cells by targeting the molecular backbone of the power-generating layer. The new design approach increased the excited state duration of the electron-accepting component, converting over 70% of light particles into current. Further modifications to the molecu...
Results from 46 patients who received targeted therapies alongside standard chemotherapy showed a 31-month average survival compared to 18 months for those without molecular changes. Targeted therapy has already improved survival for many forms of cancer and could be a game-changer for pancreatic cancer patients with specific alterations.
Researchers at Osaka University have designed and synthesized a new molecular emitter for organic light-emitting diodes (OLEDs), using rational chemical design with U-shaped synthetic building blocks. The efficient macrocyclic OLED emitter could potentially be used in tiny, energy-efficient chemical sensors.
Integral Molecular has developed a panel of fully humanized P2X7 antibodies against autoimmune disorders like atopic dermatitis and glomerulonephritis. The company's MPS Antibody Discovery platform successfully isolated high-affinity antibodies with antagonist or rare agonist activity.
Researchers at Trinity College Dublin engineer molecular sensors based on porphyrin pigments, which can detect and capture pollutants. The novel sensors exploit the shape of porphyrins to mimic a Venus flytrap's opening leaves, enabling selective binding of target molecules.
Researchers at Wyss Institute develop 'eRapid' technology enabling low-cost, handheld electrochemical devices to detect a range of biomarkers with high sensitivity and selectivity. The platform overcomes biofouling problem with simple yet robust design, allowing mass-production of biochemical sensors at low cost.
A new AI system, Generative Tensorial Reinforcement Learning (GENTRL), was used to generate six novel inhibitors of DDR1 kinase target in just 21 days. Four compounds showed activity in biochemical assays, and one lead candidate demonstrated favorable pharmacokinetics in mice.
Scientists at EPFL have found a way to generate over 9,000 macrocyclic molecules below 1 KDa with high structural diversity. The new method enables the discovery of surprisingly efficient macrocyclization reactions, leading to the identification of binders for different disease targets.
Researchers have developed artificial molecules that selectively target abnormal vascular smooth muscle cells without affecting endothelial cells. This could lead to new, safer stent treatments.
Researchers have launched an ultra-large virtual docking library with over 1 billion molecules, expanding the number of 'make-on-demand' compounds for chemical biology and drug discovery. The larger library improves its odds of weeding out inactive decoy molecules.
Researchers at Scripps Research Institute have identified an important intermediate step in how alcohol intoxication occurs. The enzyme phospholipase D2 links ethanol molecules to lipid membranes, triggering a metabolite called phosphatidylethanol that causes nerves to fire more easily, leading to hyperactivity in flies.
Scientists at Harvard University and Brigham and Women's Hospital developed a new immunoassay technique that measures extremely low concentrations of small molecules using single-molecule detection. The method was tested on two important human body molecules, cortisol and PGE2, achieving up to 50 times greater sensitivity than conventi...
Researchers create a concentrator platform with micro- and nano-structured superhydrophilic traps to increase molecule concentration by up to a million times, enabling quick identification of substances in trace amounts. The technology cuts down analysis time from days to hours and potentially achieves single-molecule detection.
Researchers identified a small molecule that activates the antioxidant response, a key mechanism to protect cells from oxidative stress. The discovery targets the glycolysis pathway, opening new strategies for treating diseases involving oxidative stress.
Researchers at the University of Toronto have discovered a way to select the outcome of chemical reactions by manipulating the 'impact parameter', a key factor in reaction dynamics. By directing reagent molecules towards targeted molecules with controlled accuracy, chemists can now control the products of chemical reactions.
Researchers found that targeting IL-1β reduced risk of gout attacks by half, with no change in serum urate levels, suggesting an independent mechanism. The study's findings could lead to new therapeutic avenues for both heart disease and crystal diseases like gout.
A team in Japan developed a new technique to detect and analyze biomolecules with inhomogeneous charge distributions by adjusting the solution. They achieved improved sensor response, allowing researchers to determine the Debye length and map out a molecule's uneven charge distributions.
Researchers at Utah State University have developed a new flavonoid molecule that can release carbon monoxide in a controlled manner, triggering cancer cell death and reducing inflammation. The unique molecules are trackable, targetable, and triggerable using visible light.
The new strategy combines design of a chemical library, virtual screening, automated synthesis, and in vitro study of biological activity. This approach accelerates and automates the process of prototype molecule optimization, increasing chances of finding potential medicinal molecules.
Researchers at UVA School of Medicine have developed a technique to manipulate molecules within cells, enabling precise targeting and minimizing side effects. This breakthrough has significant potential for treating diseases such as cancer, autism, and Alzheimer's.
A novel, affibody-based pretargeted radionuclide therapy for HER2-expressing cancers demonstrated non-toxicity to the kidneys and improved survival in mice. The treatment delivered an absorbed dose to tumors that exceeded the dose to critical organs.
Researchers have developed a novel technique that enables them to visualize biological targets in deep tissues without damaging tissues or labeling with fluorescent molecules. The method, which uses selectively guided light waves, overcomes the limitations of current optical imaging techniques.
Insilico Medicine showcases its use of artificial intelligence to identify disease targets, generate molecular structures, and track interventions for metabesity. The company aims to prevent metabolic-rooted disorders such as diabetes and dementia.
Researchers at Harvard's Wyss Institute create a DNA nanotechnology-based method, called Auto-cycling Proximity Recording (APR), that allows for repeated, non-destructive recording of molecular pairings. This enables the creation of detailed views of molecular structures and observation of different structural states.
Researchers developed an efficient method to produce antibodies that can bind to two different target molecules simultaneously, enhancing cancer immunotherapy. The new approach uses a modified IgG antibody structure with only four key changes, allowing for more versatile formats and improved stability.
A French study of 1,944 patients with advanced cancer found that comprehensive genomic profiling can guide treatment choices and lead to higher survival rates. The study's results suggest that routine genomic testing may not benefit all patients but offers hope for personalized medicine.
Scientists at the University of Alberta have developed synthetic DNA motors that can be used for improved disease detection and drug delivery. The nanomachines demonstrate the potential for early diagnosis and targeted release of drugs within patients, resulting in fewer side effects.
Researchers at the University of Warwick have identified Connexin26, a vital molecule regulating breathing, which detects CO2 levels in the bloodstream. This discovery could lead to targeted treatments for respiratory problems and congenital deafness, improving quality of life for those affected.
Researchers define how anti-cancer molecules work, binding to microtubules and destabilizing cell growth. The study's findings can be used to optimize and develop new, safer drugs.
Researchers from Cincinnati Children's Hospital Medical Center identify novel targets and molecular pathways for IPF, which inflames and scars lung tissues. Analysis of single-cell RNA sequence data reveals genetic markers linked to abnormal cell formation and loss of normal genetic control systems.
Researchers at Nagoya University have identified a novel potential target of the type 2 diabetes drug metformin: the ion exchanger protein NHX-5. In nematode worms and fruit flies, metformin targets NHX-5 to disrupt autophagy and related subcellular processes.
Researchers have identified molecular pathways required for the development of mucormycosis, a fatal infection in patients with weakened immune systems. The study provides new insights into the evolution of Mucorales fungi and offers potential therapeutic targets.
Researchers at Moffitt Cancer Center will investigate prostate cancer metastasis using a multi-disciplinary approach that integrates molecular, cellular and clinical information into mathematical models. The goal is to better understand the key factors driving disease progression and identify new therapeutic targets for prevention.
Research reveals five major ways microRNAs contribute to chemoresistance in epithelial ovarian cancer (EOC). Targeting cell cycle regulation, apoptosis, drug transporters, tumor suppressor roles, and signaling pathways can help reverse resistance. This knowledge highlights the therapeutic potential of miRNAs.